Last reviewed · How we verify
Standard dose oral anticoagulant
Standard dose oral anticoagulant is a Vitamin K antagonist (warfarin-type oral anticoagulant) Small molecule drug developed by Korea University Guro Hospital. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis. Also known as: Edoxaban of 60mg.
Standard dose oral anticoagulants inhibit vitamin K-dependent clotting factors to prevent thrombus formation.
Standard dose oral anticoagulants inhibit vitamin K-dependent clotting factors to prevent thrombus formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Standard dose oral anticoagulant |
|---|---|
| Also known as | Edoxaban of 60mg |
| Sponsor | Korea University Guro Hospital |
| Drug class | Vitamin K antagonist (warfarin-type oral anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Oral anticoagulants work by blocking the synthesis of vitamin K-dependent coagulation factors (II, VII, IX, and X) in the liver, thereby reducing the ability of blood to clot. This prevents the formation and extension of blood clots in conditions where thromboembolism is a risk. They are used for long-term anticoagulation in conditions such as atrial fibrillation, venous thromboembolism, and mechanical heart valves.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Mechanical heart valve thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- Design and Rationale of the COLT Study (PHASE3)
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (PHASE4)
- DOAC - Dosing Options in AntiCoagulation Prophylaxis (PHASE3)
- DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose oral anticoagulant CI brief — competitive landscape report
- Standard dose oral anticoagulant updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI
Frequently asked questions about Standard dose oral anticoagulant
What is Standard dose oral anticoagulant?
How does Standard dose oral anticoagulant work?
What is Standard dose oral anticoagulant used for?
Who makes Standard dose oral anticoagulant?
Is Standard dose oral anticoagulant also known as anything else?
What drug class is Standard dose oral anticoagulant in?
What development phase is Standard dose oral anticoagulant in?
What are the side effects of Standard dose oral anticoagulant?
What does Standard dose oral anticoagulant target?
Related
- Drug class: All Vitamin K antagonist (warfarin-type oral anticoagulant) drugs
- Target: All drugs targeting Vitamin K epoxide reductase complex 1 (VKORC1)
- Manufacturer: Korea University Guro Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Indication: Drugs for Mechanical heart valve thromboprophylaxis
- Also known as: Edoxaban of 60mg
- Compare: Standard dose oral anticoagulant vs similar drugs
- Pricing: Standard dose oral anticoagulant cost, discount & access